Company intelligence / Profile preview
Ufovax
Wilmington, Delaware, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Ufovax has developed a next-generation vaccine platform capable of rapidly eliciting strong B-cell (antibody) responses, demonstrated in preclinical studies with optimized antigen design (notably S2GΔHR2 for COVID-19) showing stronger neutralizing antibody production than existing spike-only approaches. IND-enabling and GMP-production work underway for COVID-19, and NIH-sponsored Phase 1 clinical trials for HIV-1 are being prepared. Multiple other preclinical vaccine candidates are in development.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineProtein nanoparticleVirus-like particleBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Scripps Research
Beyond the preview
Go deeper on Ufovax.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ufovax.